ReviewOncotarget2015
Molecular and clinical profiles of syndecan-1 in solid and hematological cancer for prognosis and precision medicine.
Review in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 95 citations in OpenAlex.
- Review
- Basigin (CD147) and calpain 4 (CapnS1) are partners in the generation of traction force but not in mechanosensing.The Journal of biological chemistry · 2026Article
- Article
- SSTNSignal transduction and targeted therapy · 2026Article
- Identification and validation of hub genes involved in papillary thyroid carcinoma progression.BMC cancer · 2026Article
- Article
- Gene expression profiling of venous malformations identifies the role of SDC1 in venous endothelial cells.Heliyon · 2024Article
- Immune cell infiltration and inflammatory landscape in primary brain tumours.Journal of translational medicine · 2024Article
- MicroRNAs as the critical regulators of epithelial mesenchymal transition in pancreatic tumor cells.Heliyon · 2024Review
- Prediction of anticancer drug sensitivity using an interpretable model guided by deep learning.BMC bioinformatics · 2024Article
- Genetic Changes in Mastocytes and Their Significance in Mast Cell Tumor Prognosis and Treatment.Genes · 2024Review
- Bioinformatics analysis of the potentially functional circRNA-miRNA-mRNA network in breast cancer.PloS one · 2024Article
- Targeted therapy for multiple myeloma: an overview on CD138-based strategies.Frontiers in oncology · 2024Review
- Multi-omic analysis of longitudinal acute myeloid leukemia patient samples reveals potential prognostic markers linked to disease progression.Frontiers in genetics · 2024Article
- Article
- Detection of COVID-19-related biomarkers by electrochemical biosensors and potential for diagnosis, prognosis, and prediction of the course of the disease in the context of personalized medicine.Analytical and bioanalytical chemistry · 2023Review
- Novel Implication of the Basement Membrane for Breast Cancer Outcome and Immune Infiltration.International journal of biological sciences · 2023Article
- Role of microRNA-494 in tumor progression.American journal of translational research · 2023Review
- CDH1 overexpression predicts bladder cancer from early stage and inversely correlates with immune infiltration.BMC urology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Syndecan-1 (SDC1, CD138) is a key cell surface adhesion molecule essential for maintaining cell morphology and interaction with the surrounding microenvironment. Deregulation of SDC1 contributes to cancer progression by promoting cell proliferation, metastasis, invasion and angiogenesis, and is associated with relapse through chemoresistance. SDC1 expression level is also associated with responses to chemotherapy and with prognosis in multiple solid and hematological cancers, including multiple myeloma and Hodgkin lymphoma. At the tissue level, the expression levels of SDC1 and the released extracellular domain of SDC1 correlate with tumor malignancy, phenotype, and metastatic potential for both solid and hematological tumors in a tissue-specific manner. The SDC1 expression profile varies among cancer types, but the differential expression signatures between normal and cancer cells in epithelial and stromal compartments are directly associated with aggressiveness of tumors and patient's clinical outcome and survival. Therefore, relevant biomarkers of SDC signaling may be useful for selecting patients that would most likely respond to a particular therapy at the time of diagnosis or perhaps for predicting relapse. In addition, the reciprocal expression signature of SDC between tumor epithelial and stromal compartments may have synergistic value for patient selection and the prediction of clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.